Researchers in Denmark are conducting preclinical studies into the utilization
of the collagen receptor uPARAP as a therapeutic target in the treatment
of mesothelioma. An initial study found that the expression of uPARAP
is abundant in mesothelioma and appears to have favorable properties for
antibody-drug conjugate (ADC) therapy.
In vivo studies in mice with mesothelioma showed that a drug targeting
uPARAP significantly delayed tumor growth and reduced tumor size compared
to control groups. Expression varied within subtypes, suggesting patient
stratification should be based on individual target expression rather
than subtype alone. An additional project is investigating uPARAP as a
target for CAR T cell therapy, but so far studies are inconclusive.
These findings highlight the potential of uPARAP as a promising therapeutic
target for mesothelioma. The study represents a significant step towards
developing an effective treatment modality, with uPARAP serving as a potential
avenue for addressing this aggressive cancer.
Read the abstract here:
The Collagen Receptor uPARAP as a Therapeutic Target for Mesothelioma